Depression and epilepsy: How closely related are they?

Neurology

Volumn 58, Issue 8 SUPPL. 4, 2002, Pages

  Kanner, Andres M ^a   Balabanov, Antoaneta ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; AMOXAPINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OXCARBAZEPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AFFECTIVE NEUROSIS; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; EPILEPSY; EPILEPTIC FOCUS; FAMILY HISTORY; FOCAL EPILEPSY; FRONTAL LOBE; GENETIC PREDISPOSITION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0037161382     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.8_suppl_5.s27     Document Type: Review

References (163)

1. Depression in epilepsy. Significance and phenomenology
2. Phenomenology of depression in epilepsy
3. Psychiatric symptom patterns of chronic epileptics attending a neurological clinic: A controlled investigation
4. Interictal behavior abnormality in temporal lobe epilepsy
5. The epidemiology of epilepsy in Rochester, Minnesota 1935-1967
6. The use of sertraline in patients with epilepsy: Is it safe?
7. Co-morbid psychiatric disorder in chronic epilepsy: Recognition and etiology of depression
8. Depression and medication toxicity, but not seizure frequency or severity, predict health outcomes in refractory epilepsy
9. Psychiatric symptom profiles of patients with epilepsy: A controlled investigation
10. The suicide rate of epilepsy
11. Suicide and epilepsy: A review of the literature
12. Depression, anxiety, and epilepsy
13. Clinical course and prognosis of temporal lobe epilepsy. A survey of 666 patients
14. Pharmacologic treatment of psychiatric disorders associated with epilepsy
15. The clinical course of epilepsy and its psychosocial correlates: Findings from a UK community study
16. Looking to the future in psychiatric epidemiology
17. Melancholia: A historical review
18. An incident case referent study of epileptic seizures in adults
19. Major depression is a risk factor for seizures in older adults
20. Depression is a risk factor for epilepsy in children
21. Psychosis, depression and epilepsy: Epidemiologic considerations
22. The neurochemistry of mood disorders: Preclinical studies
23. The catecholamine hypothesis of effective disorders: A review of supporting evidence
24. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders
25. Effects of alpha-methyl-paratyrosine (AMPT) in drug-free depressed patients
26. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting response to treatment: Preliminary findings
27. Signal transduction pathways for catecholamine receptors
28. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides
29. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: A selective monoamine oxidase inhibitor
30. L-Dopa, behavioral activation and psychopathology
31. Dextroamphetamine arousal in human subjects as a model for mania
32. Dopaminergic mechanisms in depression and mania
33. The serotonin hypothesis of major depression
34. The neurochemistry of the mood disorders
35. Biological basis of depression and therapeutic relevance
36. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders
37. GABA function in mood disorders: An update and critical review
38. Neurosteroids may differentially affect the function of two native GABA (A) receptor subtypes in the rat brain
39. Role of external and internal calcium on heterocarrier-mediated transmitter release
40. The genetically epilepsy-prone rat (GEPR)
41. Audiogenic seizures data in mice supporting new theories of biogenic amines mechanisms in the central-nervous system
42. Anti-convulsant and proconvulsant properties of viloxazine hydrochloride: Pharmacological and pharmacokinetic studies in rodents and epileptic baboon
43. Effects of several centrally active drugs on the sleep-wakefulness cycle of cats
44. Imipramine and electroshock threshold
45. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys
46. Anticonvulsant doses of carbamezapine increase hippocampal extra-cellular serotonin in genetically epilepsy-prone rats: Dose response relationships
47. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytriptamine uptake in rats
48. Rauwolfia derivates
49. The role of the neurotransmitters in the epilepsies
50. The effects of reserpine (serpasil) on the chronic disturbed schizophrenic: A comparative study of rauwolfia alkaloids and electroconvulsive therapy
51. Reserpine (Serpasil) in management of the mentally ill
52. The use of reserpine in shock-reversible patients and shock-resistant patients
53. Comparative evaluation of the safety of chlorpromazine and reserpine used in conjuction with ECT
54. Clinical and experimental investigation of the effect of imipramine on epilepsy
55. Imipramine in absence and myoclonic-astatic seizures
56. Imipramine in epilepsy
57. Effect of doxepin on seizure frequency in depressed epileptic patients
58. The anticonvulsant effect of fluoxetine in humans
59. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve
60. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihydroxy-tryptamine
61. Carbamazepine and depression
62. Interictal depression in epilepsy
63. Depression in complex partial seizures. Electroencephalography and cerebral metabolic correlates
64. Epilepsy and disorders of mood
65. Depression in patients with epilepsy: An overview
66. Some determinants of affective symptoms in epileptics
67. Depression and epilepsy
68. Interictal behavioral features of patients with epilepsy
69. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy
70. The relationship of epileptic auras and psychological attributes
71. Depression and partial epilepsy: Relevance of laterality of the epileptic focus
72. Depression, anxiety, and temporal lobe epilepsy
73. Interictal clinical manifestations of complex partial seizures
74. Cerebral metabolism and depression in patients with complex partial seizures
75. Depression in epilepsy: A common but often unrecognized maladie
76. Depression in temporal lobe epilepsy: A possible role for associated frontal lobe dysfunction?
77. Epilepsy, frontal lobe, and personality
78. Wisconsin Card Sorting Test performance in patients with complex partial seizures of temporal-lobe origin
79. Mood state in unilateral temporal lobe epilepsy
80. Executive system dysfunction in temporal lobe epilepsy: Effects of nociferous cortex versus hippocampal pathology
81. Neuropsychological characteristics of the syndrome of mesial temporal lobe epilepsy
82. A role for the hippocampus in card sorting?
83. Temporal lobe epilepsy and performance on the Wisconsin Card Sorting Test
84. Neuropsychological evidence of frontal lobe dysfunction in patients with temporal lobe epilepsy
85. Prefrontal asymmetric interictal glucose hypometabolism and cognitive impairment in patients with temporal lobe epilepsy
86. Inhibitory effects of mesial temporal partial seizures onto frontal neocortical structures
87. Affective disorders
88. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and in normal controls
89. Reduction of the prefrontal cortex glucose metabolism common to three types of depression
90. Depression and frontal lobe disorders
91. Extent of 1H spectroscopy abnormalities independently predicts mood status and quality of life in temporal lobe epilepsy
92. Adverse reactions to antiepileptic drugs: A multicenter survey of clinical practice
93. Treatment of psychiatric comorbidity in epilepsy
94. Phenobarbital treatment and major depressive disorder in children with epilepsy
95. Psychological and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants
96. Behavioral effects of carbamazepine, phenobarbital, phenytoin and primidone
97. Barbiturate anticonvulsants as a cause of severe depression
98. Vigabatrin and behavior disturbance
99. Behavioral effects of felbamate
100. Psychiatric adverse events caused by topiramate and lamotrigine: A postmarketing prevalence and risk factor study
101. Epilepsy, surgical treatment and postoperative psychiatric complications: A re-evaluation of the evidence
102. Forced normalization and the aetiology of depression in epilepsy
103. A quantitative approach to measuring the social effects of epilepsy
104. Social dimension of epilepsy: Stigma and response
105. Felt versus enacted stigma: A concept revisited
106. Sociological aspects of epilepsy
107. Epilepsy and learned helplessness
108. Psychosocial predictors of interictal depression
109. Neuropsychology
110. Social aspects of epilepsy
111. Fear of seizures and behavioral functioning in adults with epilepsy
112. Fear of seizures
113. Physical exercise, stressful life experience, and depression in adults with epilepsy
114. Cognitive impairment in epileptic patients
115. Ego functions in epilepsy
116. Animal models of mood disorders
117. Chronic mild stress-induced anhedonia: A realistic animal model of depression
118. Is the psychopathology of epilepsy different from that of non-epileptic patients?
119. The structure of emotions reflected in epileptic experiences
120. Depressive reactions associated with temporal lobe uncinate seizures
121. Ictal affect
122. Psychiatric symptoms associated with lesions of the temporal lobe
123. Ictal emotions occurring in temporal lobe dysfunction
124. Mood change preceding epileptic seizures
125. There is more to epilepsy than seizures: A reassessment of the postictal period
126. Psychiatric phenomena as an expression of postictal and paraictal events
127. The prevalence of postictal symptoms of depression in patients treated in tertiary epilepsy centers: A transcultural perspective
128. Ictal and psychiatric aspects of suicide in epileptics
129. Causative factors for suicide attempts by overdose in epileptics
130. Temporal lobe dysrhythmia and impulsive or suicidal behavior
131. Suicidal attempts in psychomotor epilepsy
132. Depression in epilepsy: Relationship to seizures and anticonvulsant therapy
133. Psychiatric morbidity in seizure patients on a neurodiagnostic monitoring unit
134. Development of a rating scale for primary depressive illness
135. An inventory for measuring depression
136. Depression in patients with epilepsy: An overview and clinical study
137. Seizures associated with antidepressants: A review
138. Anticonvulsant withdrawal-emergent psychopathology
139. Anticonvulsants for the treatment of manic depression
140. Lamotrigine in rapid-cycling bipolar disorder
141. Lamotrigine treatment of refractory bipolar disorder
142. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness
143. Tricyclic antidepressant-induced seizures and plasma drug concentration
144. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations
145. Safety of antidepressants
146. Bupropion overdose: A 3-year multicenter retrospective analysis
147. Increased carbamazepine plasma concentrations after fluoxetine coadministration
148. Interaction of fluoxetine with carbamazepine
149. Interaction between carbamazepine and fluvoxamine
150. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients
151. Lithium neuroleptic interactions: Electroencephalographic studies
152. Lithium neurotoxicity at normal therapeutic levels
153. Electroconvulsive therapy as an anticonvulsant: Implications for its mechanisms of action in affective illness
154. A study of the incidence of epilepsy following ECT
155. Electroconvulsive therapy in the high-risk patient
156. The anticonvulsant hypothesis of the mechanisms of action of ECT: Current status
157. ECT and grand mal epilepsy
158. Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT
159. Anticonvulsant and antidepressant properties of electroconvulsive therapy: A proposed mechanism of action
160. Electroconvulsive therapy for epilepsy and major depression
161. Intractable seizures, status epilepticus and ECT
162. Refractory epilepsy: An evaluation of psychological methods in outpatient management